Erythropoietin in Premature Infants to Prevent Encephalopathy
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The main goal of this trial is to investigate whether early administration of human
erythropoietin (EPO) in preterm infants improves neurodevelopmental outcome at 18 months
corrected age. This study is designed as randomized, double-masked, placebo controlled
multicenter study involving at least 312 patients.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital of Fudan University
Collaborators:
Guangzhou Women and Children's Medical Center Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital of Hubei Province Second Affiliated Hospital of Wenzhou Medical University The Maternal & Children Health Hospital of Dehong, Yunnan of China Xiamen Children's Hospital, Fujian of China